122 related articles for article (PubMed ID: 37951357)
21. Anaplastic histology Wilms' tumors registered to the Japan Wilms' Tumor Study Group are less aggressive than that in the National Wilms' Tumor Study 5.
Oue T; Koshinaga T; Takimoto T; Okita H; Tanaka Y; Nozaki M; Haruta M; Kaneko Y; Fukuzawa M;
Pediatr Surg Int; 2016 Sep; 32(9):851-5. PubMed ID: 27473009
[TBL] [Abstract][Full Text] [Related]
22. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study.
Armstrong AE; Gadd S; Huff V; Gerhard DS; Dome JS; Perlman EJ
PLoS One; 2018; 13(12):e0208936. PubMed ID: 30543698
[TBL] [Abstract][Full Text] [Related]
23. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
[TBL] [Abstract][Full Text] [Related]
24. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
Pasqualini C; Furtwängler R; van Tinteren H; Teixeira RAP; Acha T; Howell L; Vujanic G; Godzinski J; Melchior P; Smets AM; Coulomb-L'Hermine A; Brisse H; Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Graf N; Verschuur AC
Eur J Cancer; 2020 Mar; 128():38-46. PubMed ID: 32109849
[TBL] [Abstract][Full Text] [Related]
25. Brain metastasis of Wilms tumor with diffuse anaplasia and complex cytogenetic phenotype in a child with neurofibromatosis Type 1.
Shvartsbeyn M; Bassani L; Mikolaenko I; Wisoff JH
J Neurosurg Pediatr; 2011 Oct; 8(4):353-6. PubMed ID: 21961578
[TBL] [Abstract][Full Text] [Related]
26. p53 expression in Wilms' tumor: a possible role as prognostic factor.
Beniers AJ; Efferth T; Füzesi L; Granzen B; Mertens R; Jakse G
Int J Oncol; 2001 Jan; 18(1):133-9. PubMed ID: 11115550
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
Rakheja D; Khokhar S; Mitui M; Cost NG
Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
[TBL] [Abstract][Full Text] [Related]
28. Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line.
Hazen-Martin DJ; Re GG; Garvin AJ; Sens DA
Am J Pathol; 1994 May; 144(5):1023-34. PubMed ID: 8178926
[TBL] [Abstract][Full Text] [Related]
29. TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia.
Wegert J; Vokuhl C; Ziegler B; Ernestus K; Leuschner I; Furtwängler R; Graf N; Gessler M
J Pathol Clin Res; 2017 Oct; 3(4):234-248. PubMed ID: 29085664
[TBL] [Abstract][Full Text] [Related]
30. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa.
Murphy AJ; Axt JR; de Caestecker C; Pierce J; Correa H; Seeley EH; Caprioli RM; Newton MW; de Caestecker MP; Lovvorn HN
Int J Cancer; 2012 Sep; 131(6):E983-94. PubMed ID: 22437966
[TBL] [Abstract][Full Text] [Related]
32. Histological analysis of aggressiveness and responsiveness in Wilms' tumor.
Beckwith JB; Zuppan CE; Browning NG; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):422-8. PubMed ID: 8827069
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
Salama A; Kamel A
J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of histopathological response to preoperative chemotherapy in unilateral Wilms' tumor: An analysis of 899 patients treated on the SIOP WT 2001 protocol in the UK-CCLG and GPOH studies.
Vujanić GM; D'Hooghe E; Graf N; Vokuhl C; Al-Saadi R; Chowdhury T; Pritchard-Jones K; Furtwängler R
Int J Cancer; 2021 Sep; 149(6):1332-1340. PubMed ID: 34109628
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
Lahoti C; Thorner P; Malkin D; Yeger H
Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
[TBL] [Abstract][Full Text] [Related]
36. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center.
Zuppan CW; Beckwith JB; Luckey DW
Hum Pathol; 1988 Oct; 19(10):1199-209. PubMed ID: 2844645
[TBL] [Abstract][Full Text] [Related]
37. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.
Malkin D; Sexsmith E; Yeger H; Williams BR; Coppes MJ
Cancer Res; 1994 Apr; 54(8):2077-9. PubMed ID: 8174107
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor.
Sredni ST; de Camargo B; Lopes LF; Teixeira R; Simpson A
Med Pediatr Oncol; 2001 Nov; 37(5):455-8. PubMed ID: 11745874
[TBL] [Abstract][Full Text] [Related]
39. Anaplastic Wilms' tumor: clinical and pathologic studies.
Bonadio JF; Storer B; Norkool P; Farewell VT; Beckwith JB; D'Angio GJ
J Clin Oncol; 1985 Apr; 3(4):513-20. PubMed ID: 2984344
[TBL] [Abstract][Full Text] [Related]
40. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
